# US 2004/0204381 A1 · Detection and treatment of glyco-enzyme-related disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204381 A1
- Document ID: US20040204381A1
- Status: Published application
- Kind: A1
- Application number: 10/844,874
- Filed: 2004-05-13
- Published: 2004-10-14
- Earliest claimed: 1997-11-12
- Inventors: Joseph R. Moskal; Hirotaka Yamamoto
- Web page: https://patentgrep.com/patent/US20040204381A1

## CPC

- C12N 9/1081: {transferring other glycosyl groups (2.4.99)}
- A61P 35/00: Antineoplastic agents
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/022: where the vector is derived from an adenovirus
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the prevention and treatment of a disease, preferably brain cancer, by administration of an isolated DNA molecule comprising a gene encoding a protein having glycosyltransferase activity to a cell involved in the disease which is preferably a glioblastoma cell. A method of treating brain cancer is provided in which a tumor cell is transfected either ex vivo or in vivo with a composition comprising a DNA molecule that encodes a protein having glycosyltransferase activity resulting in inhibition of the growth or function of that cell.

## Claims

### Claim 1

An isolated nucleic acid sequence encoding for a recombinant, replication-deficient adenovirus and a glycosyltransferase, wherein said glycosyltransferase is selected from the group consisting of α2,3-ST glycosyltransferase, α2,6-ST glycosyltransferase, HexB glycosyltransferase, Fuco glycosyltransferase, GnTIII glycosyltransferase, GnTI glycosyltransferase, SLex-ST glycosyltransferase and GnTV glycosyltransferase.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the expression of said glycosyltransferase gene is under transcriptional control of a regulator selected from the group consisting of CMV immediate-early enhancer/promoter, SV40 early enhancer/promoter, JC polyomavirus promoter, and chicken β-actin promoter.

### Claim 3 (depends on 2)

The isolated nucleic acid of claim 2, wherein the glycosyltransferase is α2,6-ST glycosyltransferase.

### Claim 4 (depends on 3)

A method for altering the expression of a glycosyltransferase within a cell, comprising stablely transfecting the isolated nucleic acid of claim 3 into the cell, such that the expression of the glycosyltransferase within the cell is altered.

### Claim 5 (depends on 4)

The method of claim 4, wherein the expression of the glycosyltransferase is increased.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cell is a brain cancer cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein the brain cancer cell is a glioma cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein the brain cancer cell is a meningioma cell.

### Claim 9 (depends on 6)

The method of claim 6, wherein the isolated nucleic acid is transfected ex vivo.

### Claim 10 (depends on 6)

The method of claim 6, wherein the isolated nucleic acid is transfected in vivo.

### Claim 11

A recombinant adenoviral particle containing a nucleic acid encoding for a glycosyltransferase wherein said nucleic acid sequence is selected from the group consisting of nucleic acid sequence encoding for α2,3-ST glycosyltransferase, α2,6-ST glycosyltransferase, HexB glycosyltransferase, Fuco glycosyltransferase, GnTIII glycosyltransferase, GnTI glycosyltransferase, SLex-ST glycosyltransferase and GnTV glycosyltransferase.

### Claim 12 (depends on 12)

The adenoviral particle of claim 12, wherein the expression of said nucleic acid encoding for a glycosyltransferase is under transcriptional control of a regulator selected from the group consisting of CMV immediate-early enhancer/promoter, SV40 early enhancer/promoter, JC polyomavirus promoter, and chicken β-actin promoter.

### Claim 13 (depends on 13)

The adenoviral particle of claim 13, wherein the glycosyltransferase is α2,6-ST glycosyltransferase.

### Claim 14 (depends on 3)

A method for altering the expression of a glycosyltransferase within a cell, comprising introducing the adenoviral particle of claim 3 into the cell, such that the expression of the glycosyltransferase within the cell is altered.

### Claim 15 (depends on 14)

The method of claim 14, wherein the expression of the glycosyltransferase is increased.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cell is a brain cancer cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the brain cancer cell is a glioma cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the brain cancer cell is a meningioma cell.

### Claim 19 (depends on 16)

The method of claim 16, wherein the isolated nucleic acid is transfected ex vivo.

### Claim 20 (depends on 16)

The method of claim 16, wherein the isolated nucleic acid is transfected in vivo.
